Phase II
Menlo Therapeutics’ cough drug fails to meet primary endpoint in phase II trial
October 9, 2018Manufacturing and Production Phase II, cough, menlo therapeutics, serlopitant
The Redwood City, California-based late stage biopharmaceutical company Menlo Therapeutics have announced that experimental drug serlopitant has failed to meet …
Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial
October 11, 2016Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma
Phase II results presented by genomics-based discovery company Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …
Retrophin announces positive Phase II results, Shkreli claims credit
September 8, 2016Research and Development Phase II, Retrophin, Shkreli, rare kidney disease
Retrophin has announced positive top-line results for trial drug sparsentan in Phase II to treat a rare kidney disorder with …
13 deaths in Aurinia’s lupus drug trial despite hitting Phase II target
August 16, 2016Manufacturing and Production, Research and Development Aurinia, Phase II, biotech, patient deaths, voclosporin
Canadian biotech Aurinia Pharmaceuticals has announced the topline Phase IIb trial results of its lupus nephritis (LN) treatment voclosporin, which …
Amgen, Novartis migraine drug meets primary endpoint in Phase II study
June 9, 2016Research and Development AMG 334, Amgen, Novartis, Phase II, chronic, erenumab, migraine
A new treatment for chronic migraine prevention, co-developed by Novartis (NYSE: NVS) and Amgen (NASDAQ: AMGN), showed a statistically significant …
Regeneron says trial drug for osteoarthritis pain meets primary endpoint in Phase II trials
May 3, 2016Manufacturing and Production, Research and Development Phase II, Regeneron Pharmaceuticals, drug trial, osteoarthritis, phase III
Regeneron Pharmaceuticals (Nasdaq: REGN) said mid-stage trials for its drug candidate to treat osteoarthritis pain med its primary endpoint. The …
Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease
April 21, 2016Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease
Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …
BioMarin announces positive data from early stage trials of haemophilia A gene therapy
April 21, 2016Research and Development BioMarin Pharmaceutical, Phase II, drug trial, haemophilia A gene therapy
BioMarin Pharmaceutical (Nasdaq: BMRN) said early-stage trials for its haemophilia A gene therapy showed encouraging data. Chief Medical Officer, Hank …
Synta Pharmaceuticals announces merger with Madrigal
April 15, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Phase II, Synta, madrigal, merger
Synta Pharmaceuticals (NASDAQ: SNTA) has announced a definitive merger agreement with Madrigal Pharmaceuticals under which the newly-formed company will focus …
Takeda in myeloma research drive
January 14, 2016Medical Communications, Research and Development Ninlaro, Phase II, Takeda, Takeda oncology, eric low, ixazomib, multiple myeloma, myeloma
Takeda is funding the research charity Myeloma UK to run a Phase II study of its multiple myeloma treatment Ninlaro, …
Roche posts positive mid-stage trial results for atezolizumab
July 13, 2015Research and Development Genentech, PD-L1, Phase II, Roche, anti-PD-L1, atezolizumab, clinical trial, immuno-oncology, personalised medicine
A cancer drug in development by Roche has performed well in a mid-phase clinical trial – prompting the Swiss firm …
GSK severe asthma drug progresses to Phase III
August 20, 2012Research and Development, Sales and Marketing Advair, GSK, Phase II, asthma, phase III
GlaxoSmithKline’s severe asthma drug mepolizumab has impressed in a mid-stage study, meaning it can now progress into Phase III testing. …
Roche’s melanoma candidate impresses in phase II trials
November 5, 2010Research and Development BRAF protein, Cancer, Phase II, Plexxikon, RG7204, Roche
Roche’s mid-stage melanoma candidate has produced positive results in a difficult to treat cancer. RG7204 is an investigational, first-in-class molecule …
IDEA Pharma appoints Tony Akiwumi
October 18, 2010Sales and Marketing Go-To-Market Strategy, IDEA Pharma, IDEAtion, Phase II, appointment, sales and marketing
Tony Akiwumi has joined Idea Pharma as director of client value, moving to the strategic marketing consultancy from Quintiles.He will lead …
Latest content
FibroFind appoints Lee Borthwick as CEO
